Small molecules and their role in effective preclinical target validation

“...high-quality chemical probes and their derivatives are invaluable to the preclinical target validation tool set, acting as powerful research tools, resource savers and a potential source for new high-quality effective medicines.”

First draft submitted: 12 May 2017; Accepted for publication: 19 May 2017; Published online: 22 August 2017

Keywords: bromodomain • chemical probe • target validation

The importance of effective target validation

As demonstrated in multiple historical analyses, there are two main causes of molecule-related clinical attrition; lack of efficacy and unacceptable toxicity, both of which can be mitigated by effective preclinical target validation. Target validation, one of the early stages of a drug discovery program, is the process of (in)validating a drug target to ensure it is significant to the intended disease, and unlikely to drive undesired toxicity. Target validation is vital in preventing late-stage failures in the clinic and, if done effectively, can avoid unnecessary patient exposure to ineffective treatments and save pharmaceutical companies both time and money. As such, target validation is increasingly treated extremely seriously, as demonstrated by the formation of innovative public–private partnerships, such as OpenTargets, seeking to provide evidence of biological validity and the possible likelihood of pharmacological intervention. Central to the variety of tools available for use in target validation are high quality small molecule chemical probes.

A chemical probe is a tool molecule that selectively binds to a target protein, used to answer questions about the target's biological function and potential role in disease [1]. The strength in target validation is directly related to the quality of the chemical probe used. Consequently, the inadvertent misuse of chemical probes, the use of under-characterized probes, and the sheer lack of

high-quality chemical probes (compared with the number of potential biological targets) can lead to inappropriate conclusions, for example, the use of curcumin as a tool for target validation, highlighted recently by Nelson *et al.* [2].

Unfortunately, curcumin is just one of many small molecules compromising attempts at target validation today. Recently however, the area of chemical probes has evolved dramatically, with experts from medicinal chemistry, pharmacology, biology, industry and academia coming together to address these issues and help learn from past mistakes. In particular, work carried out by Bunnage *et al.* has been instrumental in defining a new set of requirements. By adapting the three pillars of survival, Bunnage and co-workers created the following four guidelines for chemical probes: The probe must be able to reach the site of action at pharmacologically relevant concentrations; display *in vitro* evidence of target engagement and selectivity; provide sufficient data to assign phenotypic results to an original structure or a well-characterized derivative; and provide cellular activity data to answer a hypothesis on the role of the target [3].

In addition to these guidelines, it has become evidently important for chemical probes to be accompanied by a structurally similar negative control. In the often paraphrased words of RB Woodward “the only model system worth using is the enantiomer” and chemical probes are no exception to this,

Michael A Clegg^{1,2},
Nicholas CO Tomkinson²,
Rab K Prinjha¹ & Philip G
Humphreys^{*,1}

¹Epigenetics Discovery Performance Unit, GlaxoSmithKline R&D, Stevenage, Hertfordshire SG1 2NY, UK

²WestCHEM, Department of Pure & Applied Chemistry, University of Strathclyde, Thomas Graham Building, 295 Cathedral Street, Glasgow, G1 1XL, UK

*Author for correspondence:
philip.g.humphreys@gsk.com

newlands
press part of

although it should be noted that enantiomeric controls are not always possible. A final consideration when designing chemical probes is the importance of structural diversity. With a selection of different chemotypes comes a greater confidence in the experimental outcome, a reduced probability of finding common off targets, greater conviction that observed phenotypes are due to target engagement and compensation for the many known unknowns.

“The combination of higher quality probes and an improved awareness has already led to a number of breakthroughs...”

Although these guidelines have helped establish a new higher standard for chemical probes used within research, the transition of replacing the previously used undercharacterized chemical probes with new higher quality molecules is largely thanks to a collection of public–private consortiums such as the Structural Genomics Consortium (SGC) [4] and chemical-probes.org [5]. Partnerships such as these have sought to raise awareness of the ‘promise and perils’ of chemical probes, while providing access to all the information available on existing probes, even offering guidance on the optimal probe for a particular target and appropriate concentrations for its use.

The combination of higher quality probes and an improved awareness has already led to a number of breakthroughs in scientific research, arguably none bigger than for the BET bromodomain family, which will now be used as a case study to demonstrate the power of small-molecule chemical probes and their evolving use in target validation.

Small molecules in bromodomain target validation

In 2010, two separate groups identified I-BET762 and (+)-JQ-1 as potent and highly selective inhibitors of the BET bromodomains. In addition to being high-quality, well-characterized chemical probes, they were both also accompanied by a negative control in the form of their inactive enantiomer, allowing for phenotypic screening studies [6]. Instead of keeping this information to themselves, the structures and properties of both molecules were made available for the scientific community. Several other groups followed suit with other BET probes, such as I-BET151, PFI-1 and OXF BD 02, which together created a diverse portfolio of chemotypes, suitable to thoroughly investigate the BET bromodomains target validity. In doing so, the biological function of this family of bromodomains, and the role they play in a number of diseases, was vigorously interrogated, ultimately accelerating bromodomain drug discovery [7]. As of 2017 there are 16 BET

bromodomain clinical candidates spanning 14 different companies, underpinning the value of (+)-JQ-1 and I-BET762 as extremely successful and effective chemical probes [1,8–9].

While (+)-JQ-1 and I-BET762 are classical examples of high-quality chemical probes, there are multiple alternative approaches utilizing small molecule probes for target validation. For example, the aforementioned BET chemical probes, while being highly pan-selective for BET bromodomains over other bromodomains, all display poor selectivity within the BET subfamily, preventing the direct assignment of BET inhibitor pharmacology to a particular bromodomain target. The ‘bump-and-hole approach’, previously used in selective kinase inhibition, has attempted to address this issue, utilizing the existing probe I-BET762. Mutation of a conserved leucine residue (L94 in BRD4[1]) to a sterically smaller alanine, and the introduction of an ethyl group to an I-BET762 derivative, produced the aforementioned ‘hole’ and ‘bump’ respectively, from which BET subfamily selectivity was achieved. Displaying up to 540-fold selectivity for mutated bromodomains over wild-type, this ethyl derivative of I-BET762 was used to dissect the individual role of BRD4’s bromodomains in chromatin binding, thus demonstrating the emerging potential for the bump-and-hole technique in the generation of new selective chemical probes, and their value in the interrogation of drug targets [10].

Utilizing the structural information typically obtained during the development of chemical probes facilitates the development of bifunctional chemical biology tools. One such important research area at the interface of drug discovery, chemical biology and target validation is proteolysis targeting chimeras (PROTACs). Fundamentally, PROTACs work by combining two protein-binding regions, one region which binds to the target protein and another which binds to an E3 ligase. Together they create a bifunctional molecule capable of facilitating ubiquitination of the target protein and thus ultimately proteolysis. A recent example of this is for the potential treatment of castration-resistant prostate cancer (CRPC) where (+)-JQ-1 was used to generate ARV-771, a highly potent ($IC_{50} < 5$ nM) BET PROTAC which has been shown to selectively degrade BET proteins and induce CRPC cell apoptosis *in vitro* [11]. Furthermore, ARV-771 has also been shown to reduce the levels of two key androgen receptors (full length androgen receptor and androgen receptor variant 7) present in prostate cancer cells, both of which are strongly linked to CRPC [12]. (+)-JQ-1 based PROTACs have also been used to apparently selectively degrade BET family member BRD4, again providing more information on selective BET sub-family functional suppression [13].

Also taking advantage of structural information around (+)-JQ-1 bound to the BET bromodomains, biotin was attached via a polyethylene glycol linker to create bio-JQ1, a bifunctional small molecule capable of facile ligand-affinity capture. Used alongside Chem-seq, a parallel DNA sequencing technique, it was possible to map the direct interactions between small molecules and bromodomain containing proteins BRD2, BRD3 and BRD4 within the genome at the chromatin level, providing further insight into the mechanisms by which BET inhibitors perturb gene expression [14].

Finally, photoaffinity labeling probes are an important chemoproteomic tool due to their ability to covalently label their biological targets. Seeking to replace the acetyl lysine mimetic of the CREBBP probe SGC-CBP30, Jones and co-workers identified a novel photo-reactive tropolone warhead, and hypothesized that photoaffinity labels could be developed for bromodomains. Shown to indeed be possible, a clickable derivative was accessed which was used to understand the direct biological targets of the probe and assess BRD4 target engagement by (+)-JQ-1 [15,16]. Clickable photoaffinity labeling probes have also been used to map thousands of site-specific small-molecule protein interactions within human cells, from which more potent and selective small molecules can be optimized, presenting this technique as a versatile approach to small-molecule discovery as we advance into the future [17].

Final thoughts

As illustrated with bromodomain probe examples, the area of chemical probes is continuously evolving, with more valuable and sophisticated approaches to small molecule enabled target validation being developed constantly. This is encapsulated by recent work

investigating the role of the epigenetic reader YEATS domain containing protein ENL. Using CRISPR-Cas9 gene editing and a targeted PROTAC approach, ENL was identified as an oncogenic transcription regulator involved in acute myeloid leukemia. ENL displacement from chromatin was shown, with *in vitro* and *in vivo* evidence, to reduce oncogenic gene expression while simultaneously sensitizing leukemia cells to BET inhibitors, presenting a promising standalone epigenetic therapy for acute myeloid leukemia, or as a combination therapy with BET inhibitors [18,19]. In addition to target-specific modulation, small molecules can also be used as technology facilitators, and in the context of target validation it should be noted that CRISPR often uses small molecule enhancers to improve efficiency and precision [20].

In conclusion, high-quality chemical probes and their derivatives are invaluable to the preclinical target validation tool set, acting as powerful research tools, resource savers and a potential source for new high-quality effective medicines. This coupled with a greater understanding and appreciation of the power of high-quality chemical tools will hopefully lead to an increase in successful target validation in the future, and a reduction in clinical attrition.

Financial & competing interests disclosure

RK Prinjha and PG Humphreys are full-time employees of GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

- 1 Arrowsmith CH, Audia JE, Austin C *et al*. The promise and peril of chemical probes. *Nat. Chem. Biol.* 11, 536–542 (2015).
- 2 Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. *J. Med. Chem.* 60, 1620–1637 (2017).
- 3 Bunnage ME, Piatnitski Chekler EL, Jones LH. Target validation using chemical probes. *Nat. Chem. Biol.* 9, 195–199 (2013).
- 4 SGC | Structural Genomics Consortium. www.thesgc.org/
- 5 Chemical Probes. www.chemicalprobes.org/
- 6 Theodoulou NH, Tomkinson NCO, Prinjha RK, Humphreys PG. Progress in the development of non-BET bromodomain chemical probes. *ChemMedChem.* 11, 477–487 (2016).
- 7 Padmanabhan B, Mathur S, Manjula R, Tripathi S. Bromodomain and extra-terminal (BET) family proteins: new therapeutic targets in major diseases. *J. Biosci.* 41, 295–311 (2016).
- 8 Scott AR. Chemical probes: a shared toolbox. *Nature* 533, S60–S61 (2016).
- 9 Zhang G, Smith SG, Zhou M-M. Discovery of chemical inhibitors of human bromodomains. *Chem. Rev.* 115, 11625–11668 (2015).
- 10 Baud MGJ, Lin-Shiao E, Cardote T *et al*. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. *Science* 346, 638–641 (2014).
- 11 Raina K, Lu J, Qian Y *et al*. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. *Proc. Natl Acad. Sci. USA* 113, 7124–7129 (2016).
- 12 Krause WC, Shafi AA, Nakka M, Weigel NL. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. *Int. J. Biochem. Cell Biol.* 54, 49–59 (2014).

- 13 Zengerle M, Chan K-H, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. *ACS Chem. Biol.* 10, 1770–1777 (2015).
- 14 Anders L, Guenther MG, Qi J *et al.* Genome-wide localization of small molecules. *Nat. Biotechnol.* 32, 92–96 (2014).
- 15 Hett EC, Piatnitski Chekler EL, Basak A *et al.* Direct photocapture of bromodomains using tropolone chemical probes. *Med. Chem. Commun.* 6, 1018–1023 (2015).
- 16 Lapinsky DJ, Johnson DS. Recent developments and applications of clickable photoprobes in medicinal chemistry and chemical biology. *Future Med. Chem.* 7, 2143–2171 (2015).
- 17 Parker CG, Galmozzi A, Wang Y *et al.* Ligand and target discovery by fragment-based screening in human cells. *Cell* 168, 527–541 (2017).
- 18 Erb MA, Scott TG, Li BE *et al.* Transcription control by the ENL YEATS domain in acute leukaemia. *Nature* 543, 270–274 (2017).
- 19 Wan L, Wen H, Li Y *et al.* ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. *Nature* 543, 265–269 (2017).
- 20 Song J, Yang D, Xu J, Zhu T, Chen YE, Zhang J. RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. *Nat. Commun.* 7, 1–7 (2016).